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The myeloma bone marrow microenvironment promotes prolifera-tion of malignant plasma cells and resistance to therapy. Activationof JAK/STAT signaling is thought to be a central component of
these microenvironment-induced phenotypes.  In a prior drug repurpos-
ing screen, we identified tofacitinib, a pan-JAK inhibitor Food and Drug
Administration (FDA) approved for rheumatoid arthritis, as an agent
that may reverse the tumor-stimulating effects of bone marrow mes-
enchymal stromal cells.  Herein, we validated in vitro, in stromal-respon-
sive human myeloma cell lines, and in vivo, in orthotopic disseminated
xenograft models of myeloma, that tofacitinib showed efficacy in
myeloma models.  Furthermore, tofacitinib strongly synergized with
venetoclax in coculture with bone marrow stromal cells but not in
monoculture. Surprisingly, we found that ruxolitinib, an FDA approved
agent targeting JAK1 and JAK2, did not lead to the same anti-myeloma
effects.  Combination with a novel irreversible JAK3-selective inhibitor
also did not enhance ruxolitinib effects. Transcriptome analysis and
unbiased phosphoproteomics revealed that bone marrow stromal cells
stimulate a JAK/STAT-mediated proliferative program in myeloma cells,
and tofacitinib reversed the large majority of these pro-growth signals.
Taken together, our results suggest that tofacitinib reverses the growth-
promoting effects of the tumor microenvironment. As tofacitinib is
already FDA approved, these results can be rapidly translated into poten-
tial clinical benefits for myeloma patients.  
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ABSTRACT
Introduction
Multiple myeloma (MM) is the second most common hematologic malignancy
in the United States of America and still has no known cure. Years of research have
revealed that a major driver of malignant plasma cell proliferation, as well as ther-
apeutic resistance, is signaling to the tumor cells from the bone marrow (BM)
microenvironment.1-3 Cell types within the BM that influence myeloma cells
include mesenchymal stromal cells, osteoblasts, osteoclasts, and multiple classes of
immune cells.1-3 Overcoming the growth-promoting phenotype of the BM
microenvironment is thought to be a promising therapeutic strategy in MM.
One approach to identifying new therapeutic agents for many diseases is drug
repurposing.  In this context, a large library of drugs, all of which are either Food
and Drug Administration (FDA)-approved, or at the minimum shown to be safe in
humans, is screened against the biological system of interest.4,5  The premise
behind these screens is that small molecules, initially designed for one indication,
may actually have beneficial effects across other diseases.  In fact, the use of
thalidomide in MM is one of the most impactful examples of successful drug
repurposing.  If new indications are found for already existing drugs, clinical devel-
opment times and associated costs can be drastically
reduced, thus accelerating the potential benefits to
patients.6,7 To identify agents which may reverse the
tumor-promoting effects of the MM BM microenviron-
ment, we recently reported a repurposing screen of 2684
compounds against three MM cell lines, either grown
alone (monoculture) or in coculture with MM patient-
derived BM mesenchymal stromal cells.8 From that
screen, we identified tofacitinib citrate, an FDA-approved
small molecule for the treatment of rheumatoid arthritis
(RA), as an agent which may reverse stromal-induced
growth proliferation of malignant plasma cells. 
Tofacitinib citrate is a potent inhibitor of all four mem-
bers of the Janus kinase (JAK) family, with preferential
inhibition of JAK1 and JAK3 over JAK2 and TYK2 in cellu-
lar assays.9 JAK signaling, mediated by downstream STAT
transcription factors, is necessary for lymphocyte stimula-
tion in response to encountered antigens.10 Therefore, JAK
inhibition holds promise for the treatment of autoimmune
diseases like RA.11 In parallel, the JAKs have gained inter-
est as therapeutic targets in MM as they mediate signaling
via interleukin-6 (IL-6). IL-6 is secreted by many cell types
within the BM microenvironment, as well as by malignant
plasma cells themselves, and it is thought that prolifera-
tion of malignant plasma cells within the human BM is
dependent on this cytokine.12 This dependence on IL-6
was underscored by the recent development of a patient-
derived xenograft model of MM, where primary plasma
cell growth only occurred in immunocompromised mouse
BM after knock-in of human IL-6.13  
In fact, a number of groups have variously targeted
JAK1/JAK2,14,15 JAK2,16-18 or all four JAKs19 with reported
preclinical therapeutic efficacy in MM.  However, per the
registry at clinicaltrials.gov, none of these experimental JAK
inhibitors have entered into MM clinical trials.
Therefore, all of these agents are very far from use in MM
patients, if they ever become available.  Herein, we
demonstrate that the already FDA-approved agent tofac-
itinib has robust preclinical activity in MM models.  We
further use ribonucleic acid sequencing (RNA-seq) and
unbiased mass spectrometry-based phosphoproteomics
to delineate pro-proliferative signals from the BM stroma
and show that they are largely reversed by tofacitinib
treatment.  Furthermore, we find that an alternate repur-
posing candidate, the FDA-approved JAK1/2 inhibitor
ruxolitinib, surprisingly does not show the same anti-
myeloma properties.  Therefore, our results support the
rapid repurposing of tofacitinib as an anti-myeloma ther-
apeutic to reverse the pro-growth effects of the BM
microenvironment and potentiate the effects of existing
myeloma therapies.
Methods
Cell culture conditions
All cell lines were authenticated by DNA genotyping at ATCC.
All cells, including patient BM mononuclear cells, were main-
tained in complete media with roswell park memorial institute-
1640 (RPMI-1640; Gibco) supplemented with 10% fetal bone
serum (FBS; Gemini), 1% penicillin-streptomycin University of
California San Francisco (UCSF), and 2 mM L-Glutamine (UCSF)
with 5% CO2.  INA-6 media was supplemented with 50 ng/mL
recombinant human IL-6 (ProSpec).  Additional details are provid-
ed in the Online Supplementary Methods.
MM and bone marrow stromal cells (BMSC) coculture
and viability testing
Cocultures were seeded into 384 well plates (Corning) with the
Multidrop Combi (Thermo Scientific). 800 stromal cells were
seeded and incubated overnight. 17 hours later, 700 myeloma cells
were added on top of  the stromal cells.  On the third day, 24 hours
after the addition of myeloma cells, cocultures were treated with
tofacitinib (LC Laboratories), ruxolitinib (Selleck Chemicals),
JAK3i,20 or IL-6 blocking antibody (R&D Systems). For drug com-
bination studies, on the fourth day, melphalan (Sigma Aldrich),
carfilzomib (Selleck Chemicals), or venetoclax (Selleck Chemicals)
were additionally added to cocultures.  On the fifth day, myeloma
cell viability was detected with the addition of luciferin (Gold
Biotechnology) and read for luminescence on Glomax Explorer
plate reader (Promega) as previously described.21 For monoculture
studies cell viability was measured using CellTiter-Glo reagent
(Promega).  All measurements were performed in quadruplicate.
All viability data are reported as normalized to dimethyl sulfoxide
(DMSO)-treated cell line in monoculture.
RNA-seq
For coculture RNA-seq, 5x106 MM.1S cells were grown with
3x106 HS5 cells for 24 hours.  CD138+ enrichment to >95% was
verified by flow cytometry for mCherry expression (Online
Supplementary Figure S1A,B). MM.1S harvested from coculture, as
well as MM.1S and HS5 grown in monoculture, were then
processed for RNA-seq as previously described.22 Significantly
upregulated transcripts were identified by DESeq23 and bioinfor-
matic analysis was performed using Enrichr.24 Raw sequencing
data are available at the Gene Expression Omnibus (GEO) reposi-
tory (Accession number GSE99293). Additional details are provid-
ed in the Online Supplementary Methods.
Western Blot Analysis
Described in the Online Supplementary Methods.
Liquid chromatography–tandem mass spectrometry
phosphoproteomics
For coculture experiments, 5x106 HS5 cells were seeded into a
T75 flask. Seventeen hours later, cultures were washed with phos-
phate buffered saline (PBS), before the addition of 107 MM.1S
mC/Luc cells. Twenty-four hours later, cocultures were treated
with 1 mM tofacitinib for 1.5 hours and 24 hours.  MM.1S cells in
suspension were harvested by aspiration, centrifuged, washed
with PBS, and flash-frozen prior to analysis.  For untreated MM.1S
monoculture or HS5 monoculture experiments, 107 cells were
used.  For sample preparation, frozen cell pellets were lysed in 8
M urea. 1 mg of total protein was then reduced in tris(2-car-
boxyethyl)phosphine (TCEP) and free cysteines alkylated with
iodoacetamide. Proteins were then digested at room temperature
for 18 hours with trypsin. Peptides were desalted, lyophilized, and
enriched for phosphopeptides using immobilized-metal affinity
column (IMAC) with Fe-NTA loaded beads.25 Phosphopeptides
were analyzed on a Thermo Q-Exactive Plus mass spectrometer
coupled to a Dionex Ultimate 3000 NanoRSLC liquid chromatog-
raphy instrument with 3.5 hour linear gradient. Raw proteomic
data files are available at the ProteomXchange PRIDE repository
(Accession number PXD006581). Additional details are provided
in the Online Supplementary Methods.
Xenograft mouse model
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were obtained from
the Jackson laboratory. 106 MM.1S mC/Luc cells, stably expressing
luciferase, were transplanted via tail vein injection into each
mouse. Tumor burden was assessed through weekly biolumines-
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cent imaging, beginning 13 days after implantation and on the
same day as treatment initiation. Mice were treated for four
weeks with vehicle or tofacitinib as indicated (five mice/arm.)
Tofacitinib was formulated in 50% DMSO, 10% (polyethylene
glycol 400) PEG 400, and 40% water and administered at 21.5
mg/kg daily by continuous subcutaneous infusion. All mouse
studies were performed according to UCSF Institutional Animal
Care and Use Committee-approved protocols.
Patient samples
De-identified primary MM BM samples were obtained from
the UCSF Hematologic Malignancy Tissue Bank in accordance
with the UCSF Committee on Human Research-approved proto-
cols and the Declaration of Helsinki.  BM mononuclear cells were
isolated by density gradient centrifugation Histopaque-1077
(Sigma Aldrich), then adjusted to 2 x 105/well in a 96 well plate.
Primary cells were stimulated with 50 ng/ml recombinant human
IL-6 (ProsPec) for 17 hours before treatment with tofacitinib for 24
hours. Cells were then stained with Alexa-Fluor 647 mouse anti-
human CD138 antibody (BD Pharmingen) and SYTOX Green
(Thermo) and analyzed on a CytoFLEX instrument (BD). 
Results
Tofacitinib targets the BM microenvironment and
reverses BMSC-mediated growth promotion 
To initially validate findings from our drug repurposing
screen, we cocultured the human MM cell line MM.1S,
which was included in the screen,8 with the immortalized
BMSC lines HS5 and HS27A (Figure 1A) and low-passage
stromal cells derived from primary myeloma patient BM
(Online Supplementary Figure S1C). MM.1S cell numbers
strongly increased compared to monoculture growth after
24 hours, confirming stromal-induced proliferative signal-
ing in this cell line.  Tofacitinib treatment reduced MM.1S
cell numbers in a dose-dependent manner, such that at 
>1 mM tofacitinib, MM.1S cell numbers in coculture return
to approximately monoculture levels (Figure 1A).
Tofacitinib has no effect on MM.1S cell viability alone nor
on stromal cells alone (Figure 1B). We further studied the
effect of tofacitinib on several other MM cell lines.  In
monoculture we found that tofacitinib only demonstrates
strong anti-MM activity in the IL-6 dependent cell line
INA-6, with limited effect on the AMO-1 cell line and
minimal to no effect on the other MM cell lines (Figure
1C). We further evaluated four myeloma cell lines
(MM.1S, RPMI-8226, JJN-3, AMO-1) in which luciferase
was stably expressed, allowing for the distinction of MM
cell viability versus stromal cell viability in coculture.21
Only the stromal-responsive cell lines exhibit any sensitiv-
ity to tofacitinib treatment (Figure 1D).  Taken together,
these results suggest that tofacitinib selectively targets the
growth-promoting interaction between MM cells and the
stromal microenvironment known to occur in patients.
BMSC-mediated plasma cell proliferation is through a
mechanism partially dependent on IL-6
We next focused on the MM.1S cell line as it showed
the unique phenotype of responsiveness to tofacitinib
only in the context of stromal stimulation.  To further
characterize the nature of pro-growth signaling, we per-
formed RNA-seq on MM.1S cells grown alone or in cocul-
ture with HS5 stromal cells.  We first noticed that the most
significantly upregulated transcript in MM.1S in the cocul-
C. Lam et al.
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Figure 1. Tofacitinib inhibits stromal cell-mediated proliferation in MM cells. A. Tofacitinib has no effect vs. MM.1S MM cells in monoculture, but instead reverses
proliferation induced by BMSC lines HS5 and HS27A. B. Tofacitinib has no viability effect vs. BMSC C. Tofacitinib has limited or minimal effects vs. most MM cell lines
in monoculture, except the IL-6 dependent line INA-6. D. In stromal cell coculture, tofacitinib does not have anti-MM effects vs. JJN-3 and RPMI-8226 cell lines, which
do not proliferate in response to stroma, but shows strong reversal of proliferation in both MM.1S and AMO1 lines. All error bars represent +/- S.D. from CellTiter-Glo
assay performed in quadruplicate in 384-well plates. PBS: phosphate buffered saline. 
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ture setting was SOCS3, part of a well-characterized neg-
ative feedback mechanism strongly induced by JAK-STAT
activation10 (Figure 2A). We further examined all 67 tran-
scripts significantly upregulated in MM.1S in the coculture
vs. monoculture setting (P< 0.005 per DESeq tool;23 listed
in Online Supplementary Dataset S1).  Using the Enrichr
tool,24 ChIP-X enrichment analysis (ChEA) of chromatin
immunoprecipitation  sequence (ChIP-seq) datasets26
found the most significant enrichment of STAT3-binding
sites at the promoter of these upregulated transcripts,
among all transcription factors (Figure 2B). Furthermore,
Protein ANalysis THrough Evolutionary Relationships
(Panther)27 pathway analysis found the only two signifi-
cantly enriched pathways to be related to JAK/STAT sig-
naling and interleukin signaling (Figure 2C).  Taken togeth-
er, these RNA-seq findings suggest that factors secreted
from stromal cells mediate proliferation by activating
JAK/STAT signaling, with STAT3 playing a central role.28
Notably, similar activation of SOCS3 and related
JAK/STAT genes were previously found after exposure to
IL-6 in the INA-6 cell line.29
However, using recombinant cytokines, even at high
concentrations of IL-6, we did not observe the same
degree of growth promotion as coculture with stromal
cells (Figure 2D).  A recent study identified other cytokines
besides IL-6 highly secreted from HS5 stromal cells.30 We
tested four of these: macrophage inflammatory protein 3A
(MIP-3A), interleukin-8 (IL-8), granulocyte colony stimu-
lating factor (G-CSF), granulocyte-macrophage colony
stimulating factor (GM-CSF), and none showed any
growth promotion (Figure 2D). Furthermore, an IL-6
blocking antibody could only partially reverse stromal cell
effects at the highest achievable concentration (Figure 2E).
These findings support the role of IL-6 in this system, but
also indicate that other factors likely play a role in MM
growth promotion.
Tofacitinib inhibits JAK/STAT signaling
Given our results above, we chose to further evaluate
downstream effects of tofacitinib inhibition of the
JAK/STAT pathway. Two of the primary downstream
mediators of IL-6 receptor and JAK activation are thought
to be pro-proliferation signaling by STAT3 and inhibitory
signaling by STAT1.28 We found that STAT3 and STAT1
phosphorylation in MM.1S dramatically increases when
in coculture with HS5 (Figure 3A,B). 1 mM tofacitinib
inhibits STAT3 phosphorylation in MM.1S cells in cocul-
ture almost to monoculture level by two hours of treat-
ment. In addition, phosphorylation of JAK1, JAK2, and
TYK2, which can also activate STAT3, were studied.  We
found evidence of a “rebound” effect by 24 hours of treat-
ment, mediated by well-characterized feedback mecha-
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Figure 2. Stromal-induced signatures in MM.1S identified by transcriptome analysis. A. Examples of significantly upregulated genes in MM.1S cells cocultured with
HS5 stromal cells in comparison to MM.1S grown in monoculture. B. ChEA analysis of 67 significantly upregulated transcripts from untreated MM.1S in HS5 coculture
vs. monoculture (P<0.005 based on DESeq analysis) demonstrates a significant enrichment of STAT3 transcription-factor binding sites based on ChIP-seq data. C.
Panther pathway analysis of this gene list demonstrates significant upregulation of interleukin signaling and JAK-STAT signaling. D. Recombinant cytokines known to
be secreted from HS5 stromal cells30 were tested for their ability to promote MM.1S proliferation. Up to the maximum achievable concentration, neither IL-6 alone nor
a combination of all tested cytokines could recapitulate the growth promotion induced by BMSC. E. An IL-6 neutralizing antibody could partially reverse stromal-
induced proliferation of MM.1S. All error bars represent +/- S.D. from CellTiter-Glo assay performed in quadruplicate in 384-well plates. PBS: phosphate buffered
saline; RNA-seq: ribonucleic acid sequencing; ChIP-seq: chromatin immunoprecipitation sequencing.
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nisms,10 serving to phosphorylate the JAKs and subse-
quently re-activate STAT3.  Despite this rebound of
STAT3 activation, however, MM growth continues to be
inhibited based on the dose-response results of tofacitinib.
In INA-6 cells we found similar effects of decreased
STAT3 phosphorylation after tofacitinib treatment and a
rebound at 24 hours (Online Supplementary Figure S2A).
As tofacitinib is known to potently inhibit JAK3, of
additional interest was an increase in JAK3 expression in
MM.1S in coculture versus monoculture, found both by
RNA-seq (Figure 2A) and Western blot (Figure 3C).
However, tofacitinib did not lead to any significant
decrease in JAK3 phosphorylation (Figure 3C).  We also
evaluated signaling through JAK3’s primary pro-prolifera-
tive downstream mediator STAT5.31 We found no evi-
dence of STAT5 phosphorylation in either monoculture or
coculture (Online Supplementary Figure S2B).  These results
suggest that JAK3/STAT5 signaling is less central to stro-
ma-supported MM growth.  We further confirmed this
result using JAK3i, a newly-described, highly-specific, irre-
versible JAK3 inhibitor.31 JAK3i had no effect on MM.1S
in mono- or coculture (Figure 4A), nor did it show any
synergy with carfilzomib treatment (Online Supplementary
Figure S2C,D). 
Taken together, these results suggest a mechanism
whereby stromal cell-induced MM proliferation is mediat-
ed through STAT3 transcriptional effects.  These signaling
pathways are inhibited by tofacitinib, ultimately leading
to the  reversal of the proliferation phenotype.
Ruxolinitib has less anti-MM activity than tofacitinib
Given that our results above suggest a more important
role for JAK1 and/or JAK2 in stromal-induced MM prolif-
eration than JAK3, we turned to an alternate candidate for
drug repurposing, ruxolinitib. This agent is FDA-approved
for use in myeloproliferative neoplasms and has much
higher affinity for JAK1 and JAK2 over JAK3 or TYK2.32
Ruxolitinib had minimal effects versus RPMI-8226 or JJN-3
cells, and, surprisingly, treatment of MM.1S actually
showed a promotion of growth at higher concentrations,
both in the monoculture and coculture settings (Figure
4B,C). Western blotting demonstrated that 1 mM ruxoli-
tinib was unable to inhibit STAT3 activation in MM.1S in
coculture (Figure 4D). In fact, STAT3 phosphorylation
increased after two hours of treatment, consistent with
the pro-proliferative effect seen in Figure 4B,C. We found
that combining ruxolitinib with JAK3i was also insuffi-
cient to recapitulate tofacitinib’s effects in mono- or cocul-
ture (Figure 4E,F). Taken together, these findings suggest
that ruxolitinib is unable to inhibit pro-proliferative
STAT3 signaling in MM.1S cells, thereby supporting tofac-
itinib as having greater potential as a repurposed anti-MM
therapy.
Unbiased phosphoproteomics demonstrates that 
tofacitinib broadly reverses pro-growth signaling
induced by bone marrow stroma
Our targeted investigations above specifically focused
on the JAK/STAT pathway. To further elucidate the mech-
anism of tofacitinib in this system, as well as gain a broad-
er view of stromal-induced proliferation and signaling in
MM cells, we pursued unbiased mass spectrometry (MS)-
based phosphoproteomics.  We studied four samples, per-
formed in biological replicate: 1) MM.1S cells in monocul-
ture, MM.1S cells in coculture, either 2) untreated (DMSO
control), 3) treated with 1 mM tofacitinib for 1.5 hours, or
4) treated with 1 mM tofacitinib for 24 hours.  We harvest-
ed MM.1S cells in suspension, enriched for phosphorylat-
ed peptides using immobilized metal chromatography,
and analyzed by liquid chromatography-tandem mass
spectrometry  (LC/MS-MS) with peptide quantification
performed using MaxQuant.33  
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Figure 3.  Tofacitinib inhibits JAK/STAT signaling in MM cells in a time-dependent manner. A. Western blotting demonstrates a marked increase in STAT3 phospho-
rylation in untreated coculture vs. monoculture in MM.1S cells. After treatment with 1 mM tofacitinib there is a rapid decrease in STAT3 phosphorylation with rebound
by 24 hours. B. STAT1 phosphorylation is also increased in response to coculture and rapidly reversed by tofacitinib treatment. C. While coculture increases JAK3 pro-
tein expression, there does not seem to be any significant change in signaling via JAK3 after tofacitinib based on phosphorylation status. Western blots are repre-
sentative of assays performed in biological duplicate. Monocult: monoculture; Cocult: coculture.
A B
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In total, 4862 phosphopeptides had intensity data in all
four samples and were used for further analysis (listed in
Online Supplementary Dataset S2). >99% of these sites are
serine and threonine phosphorylation events, consistent
with other phosphoproteomic studies using this enrich-
ment method.34 We first evaluated for phosphosites with
>4-fold intensity increases in untreated coculture vs.
monoculture.  Using our RNA-seq data as a proxy for pro-
tein-level changes, we verified these phospho-site changes
were largely driven by changes in signaling and not pro-
tein abundance (Online Supplementary Figure S3A).  Panther
pathway analysis revealed the only significantly enriched
pathway among the 544 upregulated phosphosites to be
JAK/STAT signaling (Figure 5A). However, based on
kinase enrichment analysis,35 we found enriched signa-
tures not only of JAK1 substrates, but also of other kinases
driving proliferation and the cell cycle, such as mTOR,
CDK1, and CDK2 (Figure 5B). These findings demonstrate
that unbiased phosphoproteomics can uncover broad sig-
naling effects of the BM microenvironment even down-
stream of JAK/STAT.
Next, for validation of the effects of tofacitinib treat-
ment, we first examined Ser727 on STAT3 (Figure 5C), a
known JAK-responsive phosphosite.28 Our quantitative
MS results were remarkably in line with Western blotting
for another JAK-responsive phosphosite on STAT3,
Tyr707 (Figure 3A), with a very large increase in both
phosphosites in untreated coculture compared to baseline,
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Figure 4. Ruxolitinib demonstrates less anti-MM activity than tofacitinib. A. A highly selective, irreversible inhibitor of JAK3, JAK3i, does not have any effects on
MM.1S either in monoculture or in coculture with HS5. B. The JAK1/2 inhibitor ruxolitinib has minimal anti-MM effects in monoculture vs. three MM cell lines, and
in fact appears to promote growth of MM.1S at higher concentrations. C.  A similar phenomenon is noted in HS5 coculture. D. Ruxolitinib does not inhibit, but in fact
increases signaling via STAT3 in MM.1S grown in HS5 coculture. E.-F. Combination of ruxolitinib with JAK3i, to achieve simultaneous JAK1/2/3 inhibition, does not
recapitulate effects of tofacitinib in MM.1S. All error bars represent +/- S.D. from CellTiter-Glo assay performed in quadruplicate in 384-well plates. Monocult: mono-
culture; Cocult: coculture; PBS: phosphate buffered saline. 
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a >2-fold decrease in phosphorylation after short-term
tofacitinib treatment, and a rebound in phosphorylation at
24 hours.
This finding both serves to validate our phosphopro-
teomic data as well as help us define a signature of tofac-
itinib-responsive phosphosites. Remarkably, 336 of the
544 up-regulated phosphosites in untreated coculture vs.
monoculture (62%) met the same criteria of being tofaci-
tinib-responsive (Figure 5D,E).  Furthermore, examination
across all measured phosphosites demonstrated that while
phosphorylation is broadly increased in the coculture set-
ting, noted as a general shift toward positive phosphosite
intensities in the untreated sample, treatment with tofaci-
tinib largely reverses this finding, recreating a normal dis-
tribution around the intensity values found in monocul-
ture (Figure 5F).  Taken together, these findings demon-
strate that tofacitinib broadly reverses the signaling path-
ways driving stromal-induced proliferation in MM cells,
both at the level of direct JAK targets as well as down-
stream proliferative signals, informing our mechanistic
understanding of this treatment beyond targeted Western
blots alone.
As a comparator, we also performed unbiased phospho-
proteomics of HS5 stromal cells after 1.5 hours tofacitinib
treatment. We found many fewer significantly changed
phosphosites than identically-treated MM.1S in HS5
coculture (Online Supplementary Figure S3B,C), consistent
with the lack of viability change after tofacitinib against
HS5 alone (Figure 1B).
Phosphoproteomics does not reveal specific off-target
activity for tofacitinib
Another advantage of unbiased phosphoproteomics is
potentially detecting additional off-target effects mediat-
ing tofacitinib response.  We filtered for peptides that
appeared unaffected by stromal-induced signaling (less
than +/- 50% intensity change in untreated coculture vs.
monoculture) that decreased in intensity >4-fold after 1.5
hours tofacitinib treatment (Figure 6A). We identified only
54 peptides that fit this filter, and neither Panther nor
C. Lam et al.
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Figure 5. Unbiased phosphoproteomics reveals that tofacitinib broadly reverses pro-growth signaling from stroma to MM cells. A. Analysis of 4862 phosphorylation
sites quantified by LC-MS/MS on biological replicate samples revealed 544 phosphosites to be upregulated 4-fold in untreated MM.1S in coculture with HS5 vs.
monoculture. Of these upregulated phosphopeptides, Panther pathway analysis showed JAK/STAT signaling to be the only significantly enriched pathway (P=0.036).
B. Kinase enrichment analysis demonstrated that many of the upregulated phosphopeptides derive from known substrates of other kinases related to proliferation,
such as mTOR, CDK1, and CDK2, as well as JAK1. Phosphorylated protein substrates are on the left and enriched kinases across the top.  Length of red bar in kinase
name is indicative of strength of enrichment. C. Quantitative phosphoproteomic intensity of the JAK-responsive phosphosite Ser727 on STAT3, both in untreated cocul-
ture vs. monoculture, and after tofacitinib treatment, is very similar to the pattern found by Western blotting for the other known JAK responsive STAT3 phosphosite
Tyr707 (Figure 3A), serving to validate this proteomics approach. D. Dynamics of all phosphosites found to be responsive to tofacitinib based on the criteria: 1)
increased 4-fold in coculture vs. monoculture, 2) decreased at least-2 fold from untreated coculture after 1.5 hours of 1 mM tofacitinib treatment, and 3) phosphosite
intensity remains below the untreated coculture level after 24 hours of tofacitinib treatment. E. Of 544 upregulated phosphopeptides in coculture, 336 (62%) were
defined as being tofacitinib-responsive using the criteria in D. F. Examining the global phosphosite intensity across all  quantified phosphopeptides demonstrates a
general increase in phosphorylation of MM.1S proteins in untreated coculture with HS5 (“Cocx DMSO”; note shift of distribution maximum to log2-fold change vs.
monoculture of ~1) which is then broadly reversed by tofacitinib treatment. Tof: tofacitinib; monocx: monoculture; cocx: coculture.
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kinase enrichment analysis identified any enriched signa-
tures (data not shown). Given the small number of peptides
and lack of any biological signatures, it appears most likely
these 54 peptides are background noise in the data and do
not reveal any specific off-target effects of tofacitinib.
To further investigate the possibility of any off-target
effects of tofacitinib, we downloaded available data from
the LINCS KINOMEscan database and plotted versus the
human kinase phylogenetic tree (Online Supplementary
Figure S4). These results demonstrate that, at least in cell-
free assays, tofacitinib shows much greater specificity for
JAK-family kinases compared to ruxolitinib.  Together,
these findings suggest that tofacitinib’s effects in this
coculture model appear to be due to on-target activity.
However, these results do not rule out off-target effects of
tofacitinib not detected by these analyses herein.  
Tofacitinib synergizes strongly with venetoclax only in
the coculture setting
To begin to identify potential rational combinations
with myeloma therapies, we first studied tofacitinib in
combination with carfilzomib in MM.1S cells.  Based on
zero-inflated Poisson regression (ZIP) model scoring,30,36
we found very mild synergy with this proteasome
inhibitor in both monoculture or HS5 coculture (Online
Supplementary Figure S5). Subsequently, inspired by recent
findings in acute myeloid leukemia (AML) primary sam-
ples,30 we tested the combination of tofacitinib and the
Bcl-2 inhibitor venetoclax, a promising investigational
agent in MM.37  Intriguingly, similar to the findings in
AML, we found strong synergy of these two agents only
in the coculture context but not in monoculture (Figure 6).
Tofacitinib has anti-MM activity in the BM 
microenvironment in vivo 
Toward the goal of repurposing tofacitinib as an anti-
MM therapy in patients, we next examined the efficacy of
tofacitinib in vivo. For this orthotopic disseminated
xenograft model, we used a  luciferase-labeled MM.1S cell
line, which specifically homes to the murine BM after
intravenous implantation in NOD scid g (NSG) mice.
Treatment was initiated after two weeks of tumor growth
and continued for four weeks at ~2/3 of the maximal tol-
erated dose of tofacitinib (21.5 mg/kg/day by subcuta-
neous infusion).38 Encouragingly, we found significantly
increased murine survival in this cell line model (Figure
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Figure 6. Tofacitinib shows synergy with venetoclax only in the coculture setting. A-B. Treatment was performed sequentially with 24 hours of tofacitinib followed by
24 hours of venetoclax at specified doses. C-D. For combination matrices, the interaction landscapes are shown in 2D plots. The ZIP method is used to calculate syn-
ergy across the landscape (red = positive score, synergistic; green = negative score, antagonistic) as well as to calculate an overall synergy score d, the difference in
percentage inhibition compared with the expected additive compound effect. The coculture results demonstrate synergy across all combinations with the strongest
synergy at high doses of venetoclax, as well as an overall very high synergy score of ~10.5 across the landscape. The monoculture results demonstrate mild antag-
onism at high venetoclax doses and overall antagonistic score of ~-1.5. Note different scale bars on each 2D landscape output from ZIP. Error bars represent +/- S.D.
from CellTiter-Glo assay performed in quadruplicate in 384-well plates. ZIP: zero-inflated Poisson regression.
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7A) as well as decreased tumor burden based on biolumi-
nescent imaging quantification (Figure 7B,C).  
We further tested tofacitinib versus two primary MM
BM samples treated ex vivo with the co-addition of 50
ng/mL IL-6.  We found modest viability effects against
malignant plasma cells (Figure 7D and Online
Supplementary Figure S6).  This result appears consistent
with our in vitro and phosphoproteomic results, which
suggest that plasma cell proliferation is necessary for
tofacitinib to have significant effects.  Primary MM plas-
ma cells isolated ex vivo in 2D culture are known to mini-
mally proliferate even in the presence of cytokines or stro-
mal stimulation.39 Therefore, these results may not fully
reflect the potential therapeutic efficacy of tofacitinib in
MM patients, where plasma cells are constantly proliferat-
ing within the BM.
Discussion
Given the importance of the BM microenvironment for
MM pathogenesis, the JAK/STAT signaling axis has gener-
C. Lam et al.
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Figure 7. Tofacitinib has anti-MM activity in vivo and versus primary samples ex vivo. Luciferase labeled-MM.1S MM cells were implanted intravenously into NSG
mice and tumors allowed to grow for 13 days. Mice were randomized (n=5 mice per arm) and drug dosing was then begun for four weeks. Tofacitinib dose = 21.5
mg/kg/day by subcutaneous pump. A. Tofacitinib significantly increased survival of NSG mice in these aggressive mouse models of MM by log-rank test.  B. Example
bioluminescent images from MM.1S study showing prominent localization of tumor cells to hind limb BM. C. Bioluminescence imaging quantification of tumor burden.
Error bars represent +/- S.D. D. Primary CD138+ plasma cells from two patients show modest response to 24 hour tofacitinib treatment when cultured ex vivo (with
addition of 50 ng/mL IL-6 to the media) and measured by flow cytometry (n = 2 technical replicates). Veh: vehicle; Tof: tofacitinib; DMSO: dimethyl sulfoxide.
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ated significant interest as a therapeutic target in MM.
JAK inhibition has already been validated in a number of
preclinical studies as a way to target this pathway.14-19
However, the studied compounds are not yet available
clinically, and may never be.  Herein, following the results
of a large-scale repurposing screen, we validated tofaci-
tinib as a potential therapy that can be rapidly translated
into MM patients.
Using a combination of mechanistic pharmacology and
unbiased mass spectrometry-based phosphoproteomics,
we found that tofacitinib appears to reverse stromal-
induced proliferation of MM plasma cells by inhibiting
JAK/STAT signaling. Our results also support the use of
unbiased phosphoproteomics both in kinase inhibitor
evaluation and more broadly in MM biology.  While oth-
ers have shown that IL-6 can lead to increased signaling
through STAT3,40 our results suggest that additional fac-
tors derived from BMSC can lead to plasma cell prolifera-
tion.  While we were unable to identify these factors, we
did rule out a number of cytokines highly secreted by HS5
cells.30 Furthermore, given that murine IL-6 does not cross-
react with the human IL-6 receptor,41 our in vivo results also
suggest that other factors in the murine marrow microen-
vironment can stimulate JAK-STAT signaling, which is
then reversed by tofacitinib.  Candidates include leukemia
inhibitory factor (LIF), which cross-reacts between mouse
and humans,41,42 or the complex between murine IL-6 and
soluble murine IL-6 receptor,  both of which can stimulate
JAK/STAT signaling in human cells.43
Surprisingly, in our studies, we found that the FDA-
approved JAK1/2 inhibitor ruxolitinib did not lead to the
same anti-MM effects as tofacitinib.  We do note that rux-
olitinib was previously evaluated in a small trial of 13 MM
patients in combination with dexamethasone (clinicaltri-
als.gov Identifier: 00639002), and no significant anti-MM
effects were noted in this small study.  Our in vitro results
presented herein may provide a partial explanation for the
lack of ruxolitinib efficacy in that trial.  Another recent
study also found minimal anti-MM cell line effects of rux-
olitinib unless used at extremely high doses and exposure
times.44 However, it remains mechanistically unclear why
ruxolitinib is unable to block JAK-STAT signaling in these
myeloma models.
We note that our studies are undoubtedly limited in that
they are performed in MM cell lines.  While we primarily
focused our analysis on stromal-responsive lines, which
appear to better mimic the malignant plasma cell pheno-
type found in MM patients, focused clinical trials in MM
will be necessary at this point to truly evaluate whether
tofacitinib has anti-MM effects.
Toward this goal, the value of drug repurposing
becomes readily apparent. Tofacitinib can be quickly
moved into Phase I/II studies in MM as the tolerated doses
and adverse event profiles of this drug are well-character-
ized.11 Intriguingly, a patient population with both MM
and RA could readily serve as the basis of a multi-center
trial. Alternatively, a patient population with early-stage
disease, perhaps smoldering myeloma, may be the opti-
mal setting for clinical use, when plasma cells may be
most dependent on microenvironmental cues.  Our find-
ings of strong synergy between tofacitinib and venetoclax
in the context of the BM microenvironment may be rele-
vant given the exciting progress of venetoclax in the
clinic.37 This finding may also reflect a general vulnerabil-
ity specific to the BM niche, given the effectiveness of this
combination both in MM and AML.30 In conclusion, tofac-
itinib is a promising agent to reverse the tumor-prolifera-
tive effects of the BM microenvironment that can be rap-
idly repurposed to benefit MM patients.
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